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Summary.-Measurement of in vitro and in vivo resistance to daunorubicin in AML
patients suggests that there is no simple correlation between the two.
In a patient who became clinically resistant and whose cells showed a parallel
increased resistance in vitro we found the acquisition of multiple drug resistance.
The increased in vitro resistance to daunorubicin could to some extent be overcome
by conjugating daunorubicin to DNA.
DAUNORUBICIN is commonly combined
with other agents to induce remission
in patients presenting with acute myelo-
genous leukaemia (AML). For some time
the Medical Oncology Unit at St Bartho-
lomew's Hospital used a combination
of cytosine arabinoside and daunorubicin
to induce remission (Crowther et al.,
1973). Complete remission is achieved
in a significant proportion of patients.
However, despite maintenance chemo-
therapy, relapse almost inevitably occurs
and attempts to induce a second re-
mission are necessary. The incidence of
a second complete remission in this
group is considerably less than in un-
treated patients (Beard and Fairley,
1974), but the biochemical mechanism
of this resistance is not known. We
wondered whether the peripheral cells
of those AML patients who are clinically
resistant to daunorubicin might be more
resistant to daunorubicin in vitro. Using
the technique of culturing peripheral
myeloblasts from AML patients (Balkwill,
Pindar and Crowther, 1974) we examined
the drug resistance of AML cells to see
whether this is indeed the case.
METHODS
Cells were obtained from peripheral
blood at the appropriate stage ofthe patient's
disease and the heparinized white cells
separated, either by mixing with methyl
cellulose to a final concentration of 0.3%
and spinning and washing the resulting
white cell layer, or by means of the IBM
cell separator (Buckner et at., 1969). Cells
were either cultured immediately or stored
at -70°C (Powles et at., 1973) and cultured
atleisure in Microtest dishes (Falcon Plastics,
Number 3040). Cells were suspended at 106
cells/ml in culture medium (Wellcome 199
plus 10% foetal calf serum containing 0.3%
L-asparagine plus 1% glutamine) and dis-
pensed 0-2 ml/culture well. Drugs were
added immediately thereafter and the dishes
were incubated for 72 h in a 5% C02/95%
air humidified incubator at 37°C. The drug
range used was between 0 and 75 ,ug/l.
Drugs.-Daunorubicin (" Cerubidin ") is
manufactured by May and Baker Limited,
cytosine arabinoside (" Cytosar ") by Upjohn
Limited, adriamycin by Pharmitalia (UK):
Limited and puromycin by Sigma Chemical
Co. Limited. The calf thymus DNA was
Type V from Sigma and was prepared and
conjugated with daunorubicin exactly as
described by Sokal et al. (1973).
Radiochemical.-3H-thymidine 5 Ci/mmol
was obtained from the Radiochemical Centre,
Amersham, Bucks.
RESULTS
We have cultured the pre-treatment
and/or post-relapse cells from 23 patients.
After the cells had been incubated for
3 days in the presence of daunorubicin54B. J. SMITH AND D. KUND)U
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FIa. The 3H-thymidine incorporation of J.A.'s pre-treatment cells in the presence of increasing
concentrations of daunorubicin. The TI50 is seen here to be appioximately 16 ug/lI.
the ability of the cells to incorporate
3H-thymidine was measured. 3H-thy-
midine was added to the culture to give
a final concentration of 0 5 ,uCi/ml and
incubation continued for a further 16 h.
Cells were then harvested and 3H-thy-
midine uptake was measured according
to Balkwill et al. (1974). The results
of Balkwill et al. (1974) show that AML
cells cultured under these conditions are
replicating during the time we do our
assay. This strongly suggests that the
reduction we measure in 3H-thymidine
incorporation reflects cell-killing, although
we have not directly measured this.
A typical incorporation curve is shown
in the Figure. The drug concentration
at which the incorporated counts were
reduced by half (the TI50) was taken
as a guide to the in vitro drug sensitivity.
The same approximate value was repeat-
edly obtained for all cells from the
same patient, whether or not fresh or
frozen cells were used. Tables I and II
show the results obtained for our series
of patients. Table I gives the results
with pre-treatment cells; Table II shows
the results with post-relapse cells. It
can be seen that the in vitro TI50 for
most patients' cells lies between 10 and
30 /ug/l. Only in the case of P.J. is
the figure greatly different. In this case
the cells are about 10 times more resistant
to daunorubicin than any other cells
tested by us. The post-relapse cells of
A.H. and G.S. were just as sensitive
as their pre-treatment cells, even though
these patients, like P.J., had become
clinically resistant to daunorubicin and
cytosine arabinoside. We also find that
there is no correlation between in vitro
TI50 and either the rate at which blasts
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TABLE I.-In Vitro and Initial Clinical Response to Daunorubicin
(Pre-treatment Cells)
Initial white cell count
x 103/mm3 blood
(% blasts)
38 (75)
29 (30)
180 (90)
225 (95)
30 (60)
154 (96)
69 (91)
60 (95)
28 (39)
6-3 (41)
33 (59)
96 (74)
11 (90)
White cell count 10 days
after starting treatment
x 103/mm3 blood
(% blasts)
1.0 (50)
1-4 (0)
11 0 (40)
0-3 (36)*
18-0 (40)
14-0 (90)
5-5 (62)
1-0 (50)
1-2 (12)
5-0 (12)
1-9 (30)
1-9 (56)t
1-0 (70)
Daunorubicin not given clinically
TI50
pg/l
27
16
25
23
15
19
13
25
16
16
18
20
6
13
20
25
23
21
23
Clinical
outcome:
C
C
C
N
N
C
C
C
C
N
c
N
N
* Patient died on the 6th day after treatment began. The figures for the 6th day are given.
t Patient died on the 7th day after treatment began. The figures for the 7th day are given.
: C: complete remission; N: no complete remission.
The amount of daunorubicin received by a patient on the first day of treatment was calculated on
the basis ofhis surface area. As a guide, it can be said that approximately 80 mg was received by a patient
in any single dose.
TABLE II.-In Vitro and Clinical Response to Daunorubicin ofPatients after Relapse
Pre-treatment
Patient TI50 jug/l
P.J. 25
A.H.
G.S.
T.L.
S.J.
J.D.
M.B.
A.W.
R.W.
I.M.
13
16
16
18
21
Post-relapse
TI50 jg/l*
300, 300, 1000,
1000, 200, 200
38, 15, 15, 25
31, 25, 21
9, 23
20, 18
12, 21, 23
18
13
16
23, 24, 18
Post-relapse white cell count
X 103/mm3 blood
(% blasts)
240 (99)
20 (99)
10 (99)
Not given daunorubicin again
Not given daunorubicin again
Not given daunorubicin again
Not given daunorubicin
Not given daunorubicin
Not given daunorubicin
94 (75)
Post-relapse white
cell count after
ten days treatment
x 103/mm3 blood
(% blasts)
120 (99)
Clinical
result
Resistant
40 (99) Resistant
10 (99) Resistant
31 (4) Complete
remission
* Separate estimations on samples taken from patient on different occasions.
are removed from the peripheral blood
or the achievement of a complete re-
mission.
Thus it is apparent that relative
sensitivity in this in vitro test is not
a reliable guide to the clinical suscepti-
bility of AML patients to daunorubicin.
In the one case (P.J.) where clinical
resistance paralleled the acquisition of in
vitro resistance we examined the re-
sistant cells to see whether they were
also more resistant to other drugs. Table
III shows the results ofthese experiments.
It can be seen that in all cases P.J.'s
cells are more resistant than those of
W.P. and suggests that there has been
Patient
M.Bl.
J.M.
A.E.
M.C.
M.W.
W.P.
A.H.
P.J.
T.L.
G.S.
S.J.
G.H.
J.H.
R.M.C.
E.E.
E.W.
E.O.
M.B.
S.G.
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TABLE III.-In Vitro Drug Resistance in
P.J. and W.P.
Drug
Daunorubicin
Cytosine arabinoside
Adriamycin
Puromycin
Pre-treatment
cells of W.P.
TI50 /tg/l
19
2
150
25
Post-relapse
cell of P.J.
TI50 Mg/l
250
10
1500
125
The post-relapse cells of P.J. are compared
here with the pre-treatment cells of W.P. as there
were no more of P.J.'s pre-treatment cells to
compare them with.
TABLE IV.-In Vitro Drug Resistance
in a Number of AML Patients to
Daunorubicin and Daunorubicin-DNA
Patient
P.J.
W.P.
G.H.
T.L.
S.G.
TI50 ig/l
TI50 jug/l dauno-
Cells daunorubicin rubicin-DNA
Post-relapse
Pre-treatment
Pre-treatment
Pre-treatment
Post-relapse
250
21
18
14
19
145
38
16
15
25
The TI50 is calculated with respect to the
daunorubicin added to the cell cultures whether or
not it was conjugated to DNA. This experiment
has been repeated with essentially the same result.
a simultaneous acquisition of multiple
drug resistance by P.J.'s cells. This
is particularly interesting since P.J. had
never been exposed clinically to adria-
mycin or puromycin although she had
received cytosine arabinoside. It could
be that this is due to a membrane change
which might be by-passed by fixing the
daunorubicin to a large polymer such
as DNA (Sokal et al., 1973). We therefore
compared the in vitro sensitivity of
P.J.'s cells and the cells of several other
AML patients to daunorubicin conjugated
to DNA and unconjugated daunorubicin.
Table IV shows the results. It can be
seen that to some extent conjugation
of daunorubicin to DNA improves the
ability of daunorubicin to reduce 3H-
thymidine incorporation in P.J.'s cells in
vitro. In no other patient's cells is
this so.
DISCUSSION
Our results suggest that the measure-
ment of in vitro drug resistance in this
system is not a reliable indication of the
clinical response a patient will show
to drug therapy. In this study, however,
the number of patients tested is small.
In the single instance where drug
resistance in vitro parallels the clinical
picture we are struck by the simultaneous
acquisition of resistance to several drugs.
A similar cross-resistance phenomenon
has previously been reported in tissue
culture cellsexposedtoincreasing amounts
ofdrug in vitro (Minor, 1974). A possible
explanation for this cross-resistance is
that a membrane change has occurred
affecting the transport of these drugs
into the cells, and indeed membrane
changes affecting daunorubicin transport
have been reported. Ehrlich ascites cells
exposed in vitro to daunorubicin undergo
selection to produce a cell-line 5 times
more resistant to daunorubicin than the
parent cell-line (Dan0, Frederiksen and
Hellung-Larsen, 1972). This resistant
cell has been shown to be resistant
because of a permeability change and
it appears that the drug-resistance in
this instance is due to active expulsion
of daunorubicin from the cells (Dan0
1973). Attempts to demonstrate this
effect in P.J.'s cells with 3H-puromycin
have failed, however, owing to the
fragility ofthe cells after culture.
Our evidence that P.J.'s cells are
more susceptible in vitro to daunorubicin-
DNA than to unconjugated daunorubicin
is consistent with the acquisition of an
altered permeability. This finding may
indicate that in cases of clinical resistance
paralleled by in vitro resistance the
therapy might, with advantage, include
drugs conjugated to DNA or some other
large carrier molecule.
We have no experimental evidence
concerning the mechanisms by which
such variants arise. Unfortunately, al-
though the life of AML cells cultured
under these conditions can be as long
as 2-3 months (Balkwill and Oliver,
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1976) the ability of P.J.'s cells to be
trypsinized and continue to replicate
has proved inadequate to allow us to
select and investigate revertants.
We wish to record our deep sorrow
at the death ofProfessor Gordon Hamilton
Fairley without whose support and en-
couragement this work would not have
been possible.
We would also like to thank Dr
J. M. A. Whitehouse and Dr R. T. D.
Oliver for their invaluable help and
advice.
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